Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $55.5 million.

  • Heron Therapeutics' Cash & Current Investments fell 21.73% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.1 million, marking a year-over-year decrease of 28.98%. This contributed to the annual value of $59.3 million for FY2024, which is 26.27% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Cash & Current Investments is $55.5 million, which was up 36.56% from $40.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash & Current Investments ranged from a high of $257.7 million in Q2 2021 and a low of $33.2 million during Q2 2023.
  • In the last 3 years, Heron Therapeutics' Cash & Current Investments had a median value of $60.0 million in 2023 and averaged $60.6 million.
  • As far as peak fluctuations go, Heron Therapeutics' Cash & Current Investments tumbled by 67.58% in 2022, and later skyrocketed by 102.58% in 2024.
  • Over the past 5 years, Heron Therapeutics' Cash & Current Investments (Quarterly) stood at $157.6 million in 2021, then plummeted by 46.15% to $84.9 million in 2022, then fell by 5.24% to $80.4 million in 2023, then fell by 26.27% to $59.3 million in 2024, then declined by 21.73% to $55.5 million in 2025.
  • Its last three reported values are $55.5 million in Q3 2025, $40.6 million for Q2 2025, and $50.7 million during Q1 2025.